Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis

被引:2
|
作者
Motta, Francesca [1 ,2 ]
Tonutti, Antonio [1 ,2 ]
Isailovic, Natasa [2 ]
Ceribelli, Angela [1 ,2 ]
Costanzo, Giovanni [1 ,2 ]
Rodolfi, Stefano [1 ,2 ]
Selmi, Carlo [1 ,2 ]
De Santis, Maria [1 ,2 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
[2] Istituti Ricovero & Cura Carattere Sci IRCCS Human, Rheumatol & Clin Immunol, Rozzano, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
connective tissue disease; interstitial lung disease; proteomics; aptamer technology; immunology; PULMONARY-FIBROSIS; MATRIX METALLOPROTEINASE-12; BRONCHOALVEOLAR LAVAGE; ANGIOPOIETIN-2; LEVELS; LEVELS CORRELATE; INTERLEUKIN-22; SCLERODERMA; LEPTIN; EXPRESSION; CLASSIFICATION;
D O I
10.3389/fimmu.2023.1246777
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundSystemic sclerosis (SSc) is an autoimmune connective tissue disease that affects multiple organs, leading to elevated morbidity and mortality with limited treatment options. The early detection of organ involvement is challenging as there is currently no serum marker available to predict the progression of SSc. The aptamer technology proteomic analysis holds the potential to correlate SSc manifestations with serum proteins up to femtomolar concentrations.MethodsThis is a two-tier study of serum samples from women with SSc (including patients with interstitial lung disease - ILD - at high-resolution CT scan) and age-matched healthy controls (HC) that were first analyzed with aptamer-based proteomic analysis for over 1300 proteins. Proposed associated proteins were validated by ELISA first in an independent cohort of patients with SSc and HC, and selected proteins subject to further validation in two additional cohorts.ResultsThe preliminary aptamer-based proteomic analysis identified 33 proteins with significantly different concentrations in SSc compared to HC sera and 9 associated with SSc-ILD, including proteins involved in extracellular matrix formation and cell-cell adhesion, angiogenesis, leukocyte recruitment, activation, and signaling. Further validations in independent cohorts ultimately confirmed the association of specific proteins with early SSc onset, specific organ involvement, and serum autoantibodies.ConclusionsOur multi-tier proteomic analysis identified serum proteins discriminating patients with SSc and HC or associated with different SSc subsets, disease duration, and manifestations, including ILD, skin involvement, esophageal disease, and autoantibodies.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Aptamer-based Proteomic Profiling Reveals Novel Candidate Biomarkers of Myocardial Injury
    Ngo, Debby
    Sinha, Sumita
    Shen, Dongxiao
    Keyes, Michelle J.
    Shi, Xu
    Sullivan, John F. O'
    Farrell, Laurie
    Fifer, Michael A.
    Sabatine, Marc S.
    Gerszten, Robert E.
    CIRCULATION, 2016, 134
  • [42] A Highly Sensitive Proteomic Immunoassay to Identify Novel Serum Biomarkers for Multiple Sclerosis Disease Progression
    Van Lierop, Z.
    In't Veld, S.
    Noteboom, S.
    Willemse, E.
    Schoonheim, M.
    Steenwijk, M.
    Geurts, J.
    Uitdehaag, B.
    Killestein, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 155 - 155
  • [43] Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
    Alice Cole
    Christopher P. Denton
    Current Treatment Options in Rheumatology, 2022, 8 : 152 - 170
  • [44] Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
    Bonhomme, Olivier
    Andre, Beatrice
    Gester, Fanny
    de Seny, Dominique
    Moermans, Catherine
    Struman, Ingrid
    Louis, Renaud
    Malaise, Michel
    Guiot, Julien
    RHEUMATOLOGY, 2019, 58 (09) : 1534 - 1546
  • [45] Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
    Cole, Alice
    Denton, Christopher P.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2022, 8 (04) : 152 - 170
  • [46] Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
    Volkmann, Elizabeth R.
    Wilhalme, Holly
    Tashkin, Donald P.
    Kim, Grace Hyun J.
    Goldin, Jonathan
    Haussmann, Alana
    Kuwana, Masataka
    Roth, Michael D.
    Assassi, Shervin
    ARTHRITIS CARE & RESEARCH, 2025,
  • [47] Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
    Volkmann, Elizabeth
    Wilhalme, Holly
    Tashkin, Donald
    Kim, Grace
    Goldin, Jonathan
    Haussmann, Alana
    Kuwana, Masataka
    Roth, Michael
    Assassi, Shervin
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3448 - 3449
  • [48] Serum proteomic analysis reveals potential serum biomarkers for occupational medicamentosa-like dermatitis caused by trichloroethylene
    Huang, Peiwu
    Ren, Xiaohu
    Huang, Zhijun
    Yang, Xifei
    Hong, Wenxu
    Zhang, Yanfang
    Zhang, Hang
    Liu, Wei
    Huang, Haiyan
    Huang, Xinfeng
    Wu, Desheng
    Yang, Linqing
    Tang, Haiyan
    Zhou, Li
    Li, Xuan
    Liu, Jianjun
    TOXICOLOGY LETTERS, 2014, 229 (01) : 101 - 110
  • [49] Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis
    Parker, Matthew James Sinclair
    Jee, Adelle S.
    Hansen, Dylan
    Proudman, Susanna
    Youssef, Peter
    Kenna, Tony J.
    Stevens, Wendy
    Nikpour, Mandana
    Sahhar, Joanne
    Corte, Tamera J.
    RHEUMATOLOGY, 2024, 63 (11) : 2981 - 2988
  • [50] Proteomic Analysis of Cerebrospinal Fluid in Pneumococcal Meningitis Reveals Potential Biomarkers Associated with Survival
    Goonetilleke, Upali R.
    Scarborough, Matthew
    Ward, Stephen A.
    Gordon, Stephen B.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (04): : 542 - 550